硫酸羟氯喹与艾拉莫德治疗干燥综合征的效果及安全性比较  

Efficacy and safety comparison of Hydroxychloroquine Sulfate and Iguratimod in the treatment of Sjogren syndrome

作　　者：刘玲[1] 汤艳华[1] 刘炬[1] LIU Ling;TANG Yanhua;LIU Ju(Department of Rheumatology and Immunology,Jiu Jiang NO.1 People's Hospital,Jiangxi Province,Jiujiang 332000,China)

机构地区：[1]江西省九江市第一人民医院风湿免疫科,江西九江332000

出　　处：《中国当代医药》2024年第9期45-48,共4页China Modern Medicine

基　　金：江西省卫生健康委科技计划项目(202311451、20197111)。

摘　　要：目的比较硫酸羟氯喹与艾拉莫德治疗干燥综合征(SS)的效果及安全性。方法选择2019年4月至2021年5月就诊于九江市第一人民医院风湿免疫科的90例SS患者作为研究对象,根据随机数字表法将患者分为A组(n=45)和B组(n=45)。A组予硫酸羟氯喹治疗,B组予艾拉莫德治疗,均连续治疗3个月。比较两组患者的疗效、类风湿因子(RF)、红细胞沉降率(ESR)、免疫球蛋白G(IgG)、血小板计数(PLT)、炎症指标[白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、细胞间黏附分子-1(ICAM-1)]及不良反应。结果B组患者的治疗总有效率高于A组,差异有统计学意义(P<0.05);B组患者治疗后的RF、ESR、IgG水平低于A组,PLT水平高于A组,差异有统计学意义(P<0.05);B组患者治疗后的IL-6、TNF-α、ICAM-1水平均低于A组,差异有统计学意义(P<0.05);两组患者的不良反应发生率比较,差异无统计学意义(P>0.05)。结论相比羟氯喹,艾拉莫德治疗SS效果更好,可降低IgG、RF水平,抑制B细胞活性,提高PLT水平,减轻炎症反应,且安全性好。Objective To compare the efficacy and safety of Hydroxychloroquine Sulfate and Iguratimod in the treatment of Sjogren syndrome(SS).Methods Ninety SS patients admitted to the Department of Rheumatology and Immunology,Jiu Jiang NO.1 People's Hospital from April 2019 to May 2021 were selected as the research objects and divided into group A(n=45)and group B(n=45)according to random number table method.Group A was treated with Hydroxychloroquine Sulfate and group B was treated with Iguratimod for 3 months.The efficacy,rheumatoid factor(RF),erythrocyte sedimentation rate(ESR),immunoglobulin G(IgG),platelet count(PLT),inflammatory markers(interleukin-6[IL-6],tumor necrosis factor-α[TNF-α],intercellular adhesion molecule-1[ICAM-1])and adverse reactions were compared between the two groups.Results The total effective rate of group B was higher than that of group A,the difference was statistically significant(P<0.05).After treatment,the RF,ESR and IgG levels in group B were lower than those in group A,and the PLT level was higher than that in group A,the differences were statistically significant(P<0.05).The levels of IL-6,TNF-αand ICAM-1 in group B after treatment were lower than those in group A,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Compared with Hydroxychloroquine,Iguratimod has a better effect in the treatment of SS,which can reduce IgG and RF levels,inhibit B cell activity,increase PLT levels,and alleviate inflammatory response,with good safety.

关 键 词：干燥综合征 羟氯喹 艾拉莫德 类风湿因子 红细胞沉降率 

分 类 号：R593.2[医药卫生—内科学]